SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Under Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 6, 2011
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction of
9001 Spectrum Center Blvd.
San Diego, California 92123
|(Address of Principal Executive Offices)|
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|Item 8.01.||Other Events|
On Tuesday, October 4, 2011 (US time), the Australian Stock Exchange, or ASX, approved a change in the admission category of ResMed Inc. on the ASX from an ASX Listing to an ASX Foreign Exempt Listing. The change in the admission category will be effective on Thursday, October 6, 2011 (US time). ResMed will continue to be listed on the ASX through our CHESS units of foreign securities.
ResMed will continue to be subject to the ASX listing rules specifically applying to an ASX Foreign Exempt Listing. As required by those rules, we will continue to provide the ASX with public information we provide to the US Securities and Exchange Commission and the New York Stock Exchange.
We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.
|Date: October 6, 2011|| |
|By:||/s/ David Pendarvis|
|Its:||Chief Administrative Officer, Global General Counsel and Secretary|